Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 21, 23 | -0.68 Decreased by -119.35% | -0.06 Decreased by -1.03 K% |
| Aug 14, 23 | -0.68 Decreased by -518.18% | -0.06 Decreased by -1.03 K% |
| May 15, 23 | -0.60 Decreased by -900.00% | -0.50 Decreased by -20.00% |
| Mar 31, 23 | -1.50 Decreased by -2.40 K% | -1.90 Increased by +21.05% |
| Mar 30, 23 | -0.31 Decreased by -55.00% | -0.15 Decreased by -106.67% |
| Nov 14, 22 | -0.11 Increased by +64.52% | -0.12 Increased by +8.33% |
| Oct 14, 22 | -0.06 Increased by +14.29% | -0.12 Increased by +50.00% |
| Aug 15, 22 | -0.06 Increased by +28.62% | -0.12 Increased by +50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 6.11 K Decreased by -98.05% | -2.26 M Decreased by -16.24% | Decreased by -37.05 K% Decreased by -5.85 K% |
| Mar 31, 23 | 128.27 K Increased by +399.89% | -73.53 K Increased by +98.79% | Decreased by -57.33% Increased by +99.76% |
| Dec 31, 22 | 588.99 K Increased by +1.66 K% | -4.50 M Increased by +34.78% | Decreased by -764.17% Decreased by -104.18% |
| Sep 30, 22 | 42.27 K Decreased by -57.30% | -3.78 M Decreased by -100.21% | Decreased by -8.93 K% Decreased by -368.92% |
| Jun 30, 22 | 312.86 K Increased by +895.07% | -1.95 M Increased by +5.14% | Decreased by -622.43% Increased by +90.47% |
| Mar 31, 22 | 25.66 K Decreased by -90.25% | -6.09 M Decreased by -439.44% | Decreased by -23.72 K% Decreased by -5.43 K% |
| Dec 31, 21 | -37.79 K Decreased by -160.77% | -6.90 M Decreased by -38.88% | Increased by +18.26 K% Increased by +328.55% |
| Sep 30, 21 | 99.00 K Decreased by -14.33% | -1.89 M Increased by +11.49% | Decreased by -1.91 K% Decreased by -3.31% |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.